We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Blackstone (BX) Closes Clarus Buyout, Expands in Healthcare
Read MoreHide Full Article
Recently, The Blackstone Group L.P. (BX - Free Report) completed the acquisition of global life sciences investment firm, Clarus, ramping up investments in the healthcare sector. The new business will be named as Blackstone Life Sciences, while historical funds will retain the Clarus name.
Notably, Blackstone, being the second largest owner of life sciences office space in the world, has already invested more than $19 billion in healthcare and healthcare-related transactions.
Clarus, in partnership with various biopharmaceutical companies, primarily funds growth-stage investments. With offices in Boston and San Francisco, and experience of investing in more than 50 companies in biopharmaceutical, medical device and diagnostic sectors, Clarus has raised nearly $2.6 billion since inception.
With the acquisition of Clarus, Blackstone, which already manages alternative asset classes like private equity and real estate, has launched Blackstone Life Sciences Investment Platform. Through this private investment platform, the asset manager will be able to invest across various companies and products within the life sciences sector.
The main motive behind this deal is to provide necessary funding to the healthcare industry. While this industry is experiencing extraordinary growth, it lacks proper funds to advance breakthrough healthcare products to the market for addressing medical needs.
Notably, Blackstone’s inorganic growth efforts remain impressive. Moreover, the company is expected to benefit from diversified product and revenue mix. Further, its robust fund-raising ability should support profitability.
The company’s shares have gained 3.8% in the past six months against 17.3% decline recorded by the industry.
The stock currently carries a Zacks Rank #3 (Hold).
Key Picks
Greenhill & Co., Inc. has been witnessing upward estimate revisions for the past 60 days. Moreover, this Zacks #1 Ranked (Strong Buy) stock has rallied more than 20% year to date. You can see the complete list of today’s Zacks #1 Rank stocks here.
TD Ameritrade Holding Corporation (AMTD - Free Report) has been witnessing upward estimate revisions for the past 60 days. In addition, the company’s shares have gained 5.2% year to date. At present, it carries a Zacks Rank of 2 (Buy).
Great Southern Bancorp, Inc. (GSBC - Free Report) has been witnessing upward estimate revisions for the past 60 days. Additionally, the stock has jumped around 5.1% year to date. It currently holds a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Blackstone (BX) Closes Clarus Buyout, Expands in Healthcare
Recently, The Blackstone Group L.P. (BX - Free Report) completed the acquisition of global life sciences investment firm, Clarus, ramping up investments in the healthcare sector. The new business will be named as Blackstone Life Sciences, while historical funds will retain the Clarus name.
Notably, Blackstone, being the second largest owner of life sciences office space in the world, has already invested more than $19 billion in healthcare and healthcare-related transactions.
Clarus, in partnership with various biopharmaceutical companies, primarily funds growth-stage investments. With offices in Boston and San Francisco, and experience of investing in more than 50 companies in biopharmaceutical, medical device and diagnostic sectors, Clarus has raised nearly $2.6 billion since inception.
With the acquisition of Clarus, Blackstone, which already manages alternative asset classes like private equity and real estate, has launched Blackstone Life Sciences Investment Platform. Through this private investment platform, the asset manager will be able to invest across various companies and products within the life sciences sector.
The main motive behind this deal is to provide necessary funding to the healthcare industry. While this industry is experiencing extraordinary growth, it lacks proper funds to advance breakthrough healthcare products to the market for addressing medical needs.
Notably, Blackstone’s inorganic growth efforts remain impressive. Moreover, the company is expected to benefit from diversified product and revenue mix. Further, its robust fund-raising ability should support profitability.
The company’s shares have gained 3.8% in the past six months against 17.3% decline recorded by the industry.
The stock currently carries a Zacks Rank #3 (Hold).
Key Picks
Greenhill & Co., Inc. has been witnessing upward estimate revisions for the past 60 days. Moreover, this Zacks #1 Ranked (Strong Buy) stock has rallied more than 20% year to date. You can see the complete list of today’s Zacks #1 Rank stocks here.
TD Ameritrade Holding Corporation (AMTD - Free Report) has been witnessing upward estimate revisions for the past 60 days. In addition, the company’s shares have gained 5.2% year to date. At present, it carries a Zacks Rank of 2 (Buy).
Great Southern Bancorp, Inc. (GSBC - Free Report) has been witnessing upward estimate revisions for the past 60 days. Additionally, the stock has jumped around 5.1% year to date. It currently holds a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>